2 High-Profile SoCal Biotechs That Could Disappear by 2018

[mnholdem]

A Tale of 2 High-Profile SoCal Biotechs That Could Disappear by 2018

October 7, 2016
By Mark Terry, BioSpace.com Breaking News Staff

Excerpt:

Budwell writes, “MannKind probably has less than two quarters remaining in terms of a rock solid cash runway. Now, MannKind does have some additional financing options available to extend its runway, such as its $50 million or so in at-the-market (ATM) stock offerings, as well as a $30 million loan agreement with The Mann Group. But there’s no guarantee that the company will be able to access the entirety of these remaining funds. After all, it’s not exactly feasible to tap a $50 million ATM facility with a share price below a buck.”

Source: www.biospace.com/News/a-tale-of-2-high-profile-socal-biotechs-that-could/435023/source=TopBreaking

[minnlearner]

Lets hope they are incorrect. Hey, KARMA, how about an epic comeback!?? (;

[mannmade]

There is a bright side... At least they admit we could have until 2018 to prove them wrong...